WO2002020045A2 - Vaccine against microbial pathogens - Google Patents

Vaccine against microbial pathogens Download PDF

Info

Publication number
WO2002020045A2
WO2002020045A2 PCT/GB2001/003964 GB0103964W WO0220045A2 WO 2002020045 A2 WO2002020045 A2 WO 2002020045A2 GB 0103964 W GB0103964 W GB 0103964W WO 0220045 A2 WO0220045 A2 WO 0220045A2
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine
composition
gene
heat shock
microbial pathogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2001/003964
Other languages
English (en)
French (fr)
Other versions
WO2002020045A3 (en
Inventor
Camilo Anthony Leo Selwyn Colaco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunobiology Ltd
Original Assignee
Immunobiology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunobiology Ltd filed Critical Immunobiology Ltd
Priority to JP2002524528A priority Critical patent/JP2004508339A/ja
Priority to US10/363,454 priority patent/US20050232946A1/en
Priority to EP01963230A priority patent/EP1315518B1/en
Priority to DE60140681T priority patent/DE60140681D1/de
Priority to AU2001284261A priority patent/AU2001284261A1/en
Priority to DK01963230.6T priority patent/DK1315518T3/da
Priority to IL15472701A priority patent/IL154727A0/xx
Priority to CA002421229A priority patent/CA2421229A1/en
Priority to AT01963230T priority patent/ATE450270T1/de
Publication of WO2002020045A2 publication Critical patent/WO2002020045A2/en
Publication of WO2002020045A3 publication Critical patent/WO2002020045A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins

Definitions

  • the vaccine further comprises an adjuvant.
  • the vaccine composition is administered by injection.
  • the invention also provides a method for exposing an animal to a vaccine of the invention by administering a pharmaceutically acceptable quantity of the vaccine of the invention, optionally in combination with an adjuvant, sufficient to elicit an immune response in the animal .
  • the SP complexes may be used at any suitable concentration to provide the immunogenic determinant in the vaccine composition.
  • Constitutive hsp producing microbes can be constructed through the knockout of transcriptional regulator suppressor genes such as hspR, MerR (mercuric resistance operon regulatory protein) , HmrR (heavy metal regulatory protein) and their homologues or the transcriptional control genes rho and sigma.
  • transcriptional regulator suppressor genes such as hspR, MerR (mercuric resistance operon regulatory protein) , HmrR (heavy metal regulatory protein) and their homologues or the transcriptional control genes rho and sigma.
  • Such genes are readily identified by screening of genome sequence databases with typical test sequences.
  • An example of such a typical test sequence is the hspR gene of M. tuberculosis (shown in Figure 1) .
  • An example of a list of identified suppressors which have homology to the hspR gene is shown in Figure 2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PCT/GB2001/003964 2000-09-04 2001-09-04 Vaccine against microbial pathogens Ceased WO2002020045A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2002524528A JP2004508339A (ja) 2000-09-04 2001-09-04 微生物病原体ワクチン
US10/363,454 US20050232946A1 (en) 2000-09-04 2001-09-04 Vaccine against microbial pathogens
EP01963230A EP1315518B1 (en) 2000-09-04 2001-09-04 Vaccine against microbial pathogens
DE60140681T DE60140681D1 (de) 2000-09-04 2001-09-04 Impstoff gegen mikrobielle pathogenen
AU2001284261A AU2001284261A1 (en) 2000-09-04 2001-09-04 Vaccine against microbial pathogens
DK01963230.6T DK1315518T3 (da) 2000-09-04 2001-09-04 Vaccine mod mikrobielle patogener
IL15472701A IL154727A0 (en) 2000-09-04 2001-09-04 Vaccine against microbial pathogens
CA002421229A CA2421229A1 (en) 2000-09-04 2001-09-04 Vaccine against microbial pathogens
AT01963230T ATE450270T1 (de) 2000-09-04 2001-09-04 Impstoff gegen mikrobielle pathogenen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0021757.0A GB0021757D0 (en) 2000-09-04 2000-09-04 Vaccine against microbial pathogens
GB0021757.0 2000-09-04

Publications (2)

Publication Number Publication Date
WO2002020045A2 true WO2002020045A2 (en) 2002-03-14
WO2002020045A3 WO2002020045A3 (en) 2002-10-31

Family

ID=9898866

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/003964 Ceased WO2002020045A2 (en) 2000-09-04 2001-09-04 Vaccine against microbial pathogens

Country Status (15)

Country Link
US (1) US20050232946A1 (enExample)
EP (1) EP1315518B1 (enExample)
JP (1) JP2004508339A (enExample)
CN (1) CN1452495A (enExample)
AT (1) ATE450270T1 (enExample)
AU (1) AU2001284261A1 (enExample)
CA (1) CA2421229A1 (enExample)
DE (1) DE60140681D1 (enExample)
DK (1) DK1315518T3 (enExample)
ES (1) ES2337653T3 (enExample)
GB (1) GB0021757D0 (enExample)
IL (1) IL154727A0 (enExample)
PT (1) PT1315518E (enExample)
WO (1) WO2002020045A2 (enExample)
ZA (1) ZA200301759B (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008025095A1 (en) 2006-09-01 2008-03-06 Csl Limited Method of eliciting or inducing an immune response
WO2009021291A1 (en) * 2007-08-16 2009-02-19 The University Of Sydney Mycobacterium vaccine formulation
WO2010146401A1 (en) 2009-06-19 2010-12-23 Immunobiology Limited Method for the purification of protein complexes
WO2011033319A1 (en) 2009-09-21 2011-03-24 Health Protection Agency Commensal neisserial stress protein preparations
WO2012127248A1 (en) 2011-03-23 2012-09-27 Immunobiology Limited Method for the production of protein complexes and vaccine compositions comprising the same
US8999353B2 (en) 2007-10-12 2015-04-07 Csl Limited Method of eliciting an immune response against pandemic influenza virus

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7928264B2 (en) * 2004-09-21 2011-04-19 Astellas Pharma Inc. Aminoalcohol derivatives
BR112013026929A2 (pt) * 2011-04-20 2016-12-27 Mico Bio Inc composição e método para intensificação de uma resposta imune

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0506211B1 (en) * 1986-08-18 1999-03-24 British Technology Group Limited Vaccines
US5776724A (en) * 1988-10-24 1998-07-07 Yale University Chaperonin-mediated protein folding
JPH03204820A (ja) * 1989-10-12 1991-09-06 Nippon Saibai Suisan Kk エビ類の細菌性疾病予防ワクチン及びその製造法
JPH08509873A (ja) * 1993-05-19 1996-10-22 アンスティテュ・パストゥール ヘリコバクター感染に対する免疫組成物、該組成物に用いられるポリペプチドおよび該ポリペプチドをコードする核酸配列
US6258359B1 (en) * 1993-05-19 2001-07-10 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
JPH0748398A (ja) * 1993-08-03 1995-02-21 Nippon Oil Co Ltd 変性蛋白質の再生方法及び変性蛋白質再生剤
US6872542B1 (en) * 1993-11-18 2005-03-29 Siga Pharmaceuticals, Inc. Treatment or prophylaxis of diseases caused by pilus-forming bacteria
US6420127B1 (en) * 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
WO1996040928A1 (en) * 1995-06-07 1996-12-19 Biochem Vaccines Inc. Streptococcal heat shock proteins members of the hsp70 family
US5935576A (en) * 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
JP2000502054A (ja) * 1995-11-30 2000-02-22 アグリカルチャー ビクトリア サービシーズ ピーティーワイ．エルティーディー． 治療用および診断用の組成物
US6066716A (en) * 1996-09-20 2000-05-23 University Of New Mexico Purified heat shock protein complexes
US5747332A (en) * 1996-09-20 1998-05-05 University Of New Mexico Methods for purifying and synthesizing heat shock protein complexes
US6331388B1 (en) * 1997-10-17 2001-12-18 Wisconsin Alumni Research Foundation Immune response enhancer
US5948646A (en) * 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US6500434B1 (en) * 1998-04-23 2002-12-31 Medimmune, Inc. Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
AU770498B2 (en) * 1998-06-19 2004-02-26 Merieux Oravax LT and CT in parenteral immunization methods against helicobacter infection
GB9818133D0 (en) * 1998-08-19 1998-10-14 Quadrant Holdings Cambridge Vaccine
JP2002537351A (ja) * 1999-02-22 2002-11-05 ユニバーシティ・オブ・ブリティッシュ・コロンビア コーロバクターリポ多糖免疫アジュバント
US7041465B1 (en) * 1999-08-11 2006-05-09 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
GB9919734D0 (en) * 1999-08-19 1999-10-20 Colaco Camilo Vaccines from infectious agents
US6677139B1 (en) * 1999-12-23 2004-01-13 Genecor International, Inc. Methods for production of proteins in host cells
GB0004547D0 (en) * 2000-02-23 2000-04-19 Immunobiology Ltd Screening method for novel vaccine candidates and compositions obtained thereby
AU2001257087A1 (en) * 2000-04-17 2001-10-30 Mojave Therapeutics Inc. Heat shock protein-based antiviral vaccines
CN1107681C (zh) * 2000-08-11 2003-05-07 中国科学院微生物研究所 乙肝病毒抗原多肽与热休克蛋白的复合物及其应用
US6932985B2 (en) * 2000-10-10 2005-08-23 Auburn University Azide method and composition for controlling deleterious organisms
WO2002059156A2 (en) * 2000-12-22 2002-08-01 Medimmune, Inc. Therapeutic compounds structurally-linked to bacterial polypeptides
WO2003068941A2 (en) * 2002-02-13 2003-08-21 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
WO2003074003A2 (en) * 2002-03-01 2003-09-12 Applied Immune Technologies Immunogens for treatment of neoplastic and infectious disease
CA2483925A1 (en) * 2002-05-02 2004-04-29 University Of Connecticut Health Center Using heat shock proteins and alpha-2-macroglobulins to increase immune response to vaccines comprising heat shock protein-peptide complexes or alpha-2-macroglobulin-peptide complexes

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008025095A1 (en) 2006-09-01 2008-03-06 Csl Limited Method of eliciting or inducing an immune response
US9150619B2 (en) 2006-09-01 2015-10-06 Csl Limited Method of elicting or inducing an immune response
WO2009021291A1 (en) * 2007-08-16 2009-02-19 The University Of Sydney Mycobacterium vaccine formulation
US8999353B2 (en) 2007-10-12 2015-04-07 Csl Limited Method of eliciting an immune response against pandemic influenza virus
WO2010146401A1 (en) 2009-06-19 2010-12-23 Immunobiology Limited Method for the purification of protein complexes
US10040820B2 (en) 2009-06-19 2018-08-07 Immunobiology Limited Method for the purification of protein complexes
WO2011033319A1 (en) 2009-09-21 2011-03-24 Health Protection Agency Commensal neisserial stress protein preparations
WO2012127248A1 (en) 2011-03-23 2012-09-27 Immunobiology Limited Method for the production of protein complexes and vaccine compositions comprising the same
US10240179B2 (en) 2011-03-23 2019-03-26 Immunobiology Limited Method for the production of protein complexes and vaccine compositions comprising the same
US10669563B2 (en) 2011-03-23 2020-06-02 Immunobiology Limited Method for the production of protein complexes and vaccine compositions comprising the same

Also Published As

Publication number Publication date
GB0021757D0 (en) 2000-10-18
DK1315518T3 (da) 2010-04-19
AU2001284261A1 (en) 2002-03-22
IL154727A0 (en) 2003-10-31
ES2337653T3 (es) 2010-04-28
ZA200301759B (en) 2004-06-22
CN1452495A (zh) 2003-10-29
JP2004508339A (ja) 2004-03-18
EP1315518A2 (en) 2003-06-04
WO2002020045A3 (en) 2002-10-31
DE60140681D1 (de) 2010-01-14
US20050232946A1 (en) 2005-10-20
EP1315518B1 (en) 2009-12-02
PT1315518E (pt) 2010-03-05
CA2421229A1 (en) 2002-03-14
ATE450270T1 (de) 2009-12-15

Similar Documents

Publication Publication Date Title
Cassataro et al. Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection
Chambers et al. Vaccination of mice and cattle with plasmid DNA encoding the Mycobacterium bovis antigen MPB83
Hajam et al. Incorporation of membrane-anchored flagellin into Salmonella Gallinarum bacterial ghosts induces early immune responses and protection against fowl typhoid in young layer chickens
EP1315518B1 (en) Vaccine against microbial pathogens
EP1370284B1 (en) Bacteriophage-mediated immunisation
US20050175635A1 (en) Method and composition
EP1204422B1 (en) Stress-proteins from extra-cellular pathogens as vaccines against infectious agents
AU776439B2 (en) Recombinant subunit vaccine
EP4061414A1 (en) A novel vaccine against heamophilus parasuis
AU2005204321B2 (en) Vaccines from Infectious Agents
EP1204421B1 (en) Stress protein-peptide complexes as vaccines against intra-cellular pathogens
Silva et al. DNA encoding individual mycobacterial antigens protects mice against tuberculosis
Liu et al. Immunogenicity of recombinant BCGs expressing predicted antigenic epitopes of bovine viral diarrhea virus E2 gene
AU2005204218A1 (en) Vaccine Against Intra-Cellular Pathogens
Rapp Achieving protective immunity against intracellular bacterial pathogens: a study on the efficiency of Gp96 as a vaccine carrier
Stittelaar Attenuated Organisms as Vaccines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 331/CHENP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2001963230

Country of ref document: EP

Ref document number: 2003/01759

Country of ref document: ZA

Ref document number: 200301759

Country of ref document: ZA

Ref document number: 2421229

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 154727

Country of ref document: IL

Ref document number: 2002524528

Country of ref document: JP

Ref document number: 018151337

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001963230

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10363454

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642